Pfizer

Pfizer’s Hympavzi Wins FDA Expanded Approval for Haemophilia A and B

Yuvraj — Thu, 11 Jun 2026 07:19:17 +0000

Pfizer has secured an expanded indication approval from the US Food and Drug Administration (FDA) for Hympavzi (marstacimab-hncq), broadening its use in the treatment of haemophilia A or B. The updated approval extends coverage to patients aged 12 years and older who have inhibitors, and also to children between six and 11 years of age, […]

The post Pfizer’s Hympavzi Wins FDA Expanded Approval for Haemophilia A and B first appeared on World Pharma Today.

Pfizer and Chai Discovery Sign AI Licensing Deal to Accelerate Drug Discovery

Yuvraj — Sat, 06 Jun 2026 08:04:24 +0000

Pfizer has entered into a licensing agreement with Chai Discovery, granting the pharmaceutical giant access to Chai’s generative AI platform for integration into its drug discovery operations. The deal provides Pfizer with early access to the newly revealed Chai-3 model, as well as a dedicated model trained specifically on Pfizer’s proprietary data and workflows — […]

The post Pfizer and Chai Discovery Sign AI Licensing Deal to Accelerate Drug Discovery first appeared on World Pharma Today.

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

Yuvraj — Mon, 01 Jun 2026 05:50:48 +0000

The Pfizer Innovent Cancer Deal has been finalized, establishing a global licensing and collaboration agreement valued at up to $10.5 billion. The transaction focuses on the research, development, and commercialization of 12 early-stage oncology programs. This arrangement combines the capabilities of both organizations to advance a specialized therapeutic pipeline targeting complex oncology indications. Under the […]

The post Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement first appeared on World Pharma Today.

Weight-Loss Pills Mark a Turning Point for Pharma Industry

Yuvraj — Mon, 16 Feb 2026 11:58:02 +0000

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive pressures in one of the fastest-growing drug categories. The commercial success of GLP-1 receptor agonists such […]

The post Weight-Loss Pills Mark a Turning Point for Pharma Industry first appeared on World Pharma Today.

Pfizer Signs Around $2.1bn Licensing Deal with YaoPharma

Yuvraj — Thu, 18 Dec 2025 06:27:20 +0000

Pfizer has confirmed that it has struck an almost $2.1bn licensing deal with YaoPharma in order to develop as well as commercialize its obesity pill, hence furthering its push into the weight loss spectrum. It is worth noting that the oral drug of YaoPharma works by way of targeting the same gut hormone, GLP-1, which […]

The post Pfizer Signs Around $2.1bn Licensing Deal with YaoPharma first appeared on World Pharma Today.

Is US Planning Executive Order on Chinese Pharma Companies?

Yuvraj — Fri, 12 Sep 2025 08:32:15 +0000

It is worth noting that the pharmaceutical sector’s recent source of novel molecules may as well be coming under threat. Apparently, it is the White House which is reportedly preparing an executive order that is going to place restrictions on drugs brought-in to the US from China, which also includes experimental treatments which happen to […]

The post Is US Planning Executive Order on Chinese Pharma Companies? first appeared on World Pharma Today.